CRC cells treated with cetuximab showed an increase in apoptosis-related protein cleaved caspase-3 and a decrease in uncleaved PARP, as well as reductions in cell cycle-associated proteins including CDK2, cyclin E1, and cyclin D1 (Fig. S1B). This evidence concerns the gene CASP3 and colorectal carcinoma.